April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Intravitreal Bevacizumab (Avastin) for Choroidal Neovascularization Secondary to Pathologic Myopia
Author Affiliations & Notes
  • N. K. Yadav
    Department of Vitreo-Retina Services, Narayana Nethralaya, Bangalore, India
  • S. Prasad
    Department of Vitreo-Retina Services, Narayana Nethralaya, Bangalore, India
  • S. Natesh
    Department of Vitreo-Retina Services, Narayana Nethralaya, Bangalore, India
  • P. Srinivasan
    Department of Vitreo-Retina Services, Narayana Nethralaya, Bangalore, India
  • V. Kemmanu
    Department of Vitreo-Retina Services, Narayana Nethralaya, Bangalore, India
  • B. K. Shetty
    Department of Vitreo-Retina Services, Narayana Nethralaya, Bangalore, India
  • Footnotes
    Commercial Relationships  N.K. Yadav, None; S. Prasad, None; S. Natesh, None; P. Srinivasan, None; V. Kemmanu, None; B.K. Shetty, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 2279. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      N. K. Yadav, S. Prasad, S. Natesh, P. Srinivasan, V. Kemmanu, B. K. Shetty; Intravitreal Bevacizumab (Avastin) for Choroidal Neovascularization Secondary to Pathologic Myopia. Invest. Ophthalmol. Vis. Sci. 2009;50(13):2279.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the safety and efficacy of intravitreal Avastin in the treatment of myopic choroidal neovascular membrane (mCNV).

Methods: : 18 eyes of 17 patients, receiving intravitreal Avastin for mCNV were retrospectively analyzed for changes in the best corrected visual acuity(BCVA),Fluorescein angiography(FFA),and optical coherence tomography(OCT).

Results: : 18 eyes of 17 patients were followed up for a mean period of 9.27(range 6-15) months. The Mean spherical equivalent refractive error of the 18 eyes was -14.75 D (range, -6 to -24 D).The mean ± standard deviation (SD) logarithm of the minimum angle of resolution (logMAR) BCVA at baseline was 0.28±0.20 (snellen equivalent,20/80). At the last follow up the mean logMAR BCVA improved to 0.42 (snellen equivalent,20/40;p<0.003).vision improved by a mean of 1.7 (range, 0-6) lines on the snellen visual acuity chart. The mean ± SD baseline central retinal thickness (CRT) of 288±60.36µm reduced to 209µm ± 46.91µm (p<0.0001).The mean number of injections per eye was 2.8 (range1-5). Leakage from the mCNV had resolved in 15 of the 18 eyes and was reduced in 3 eyes. No ocular or systemic adverse affects were noted.

Conclusions: : Intravitreal Avastin is a safe and effective treatment option for mCNV, resulting in improved visual acuity and central retinal thickness. Larger prospective controlled trials with a longer follow up are needed to study the optimal treatment regime, safety and dosage.

Keywords: vascular endothelial growth factor • choroid: neovascularization • myopia 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×